Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued new shares to holders of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, with maturity on December 20, 2025 (the “Convertible Bonds”). Today, Alvotech issued 22,073,578 new ordinary shares in exchange for Convertible Bonds, at the fixed price of US$10.00 per share. The majority of the holders ...

Group 1 - Alvotech issued 22,073,578 new ordinary shares at a fixed price of US$10.00 per share in exchange for subordinated convertible bonds [1] - Following the conversion, the total number of issued shares in Alvotech is 324,801,040, with 301,944,470 outstanding shares [1] - The newly issued shares will be delivered to their owners no later than seven business days from the announcement [1] Group 2 - Alvotech is focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilar space [2] - The company has launched two biosimilars and has a development pipeline that includes nine disclosed biosimilar candidates targeting various diseases [2] - Alvotech has established strategic commercial partnerships across multiple regions, including the US, Europe, Japan, and parts of Asia and South America [2]

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: Strong preliminary revenue growth with total revenues for the second quarter between $196 - $201 million. Preliminary total revenues for the first six months are $233 - $238 million, an approximately 10-fold increase compa ...

REYKJAVIK, Iceland, July 01, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows: Strong preliminary revenue growth with total revenues for the second quarter between $196 - $201 million. Preliminary total revenues for the first six months are $233 - ...

REYKJAVIK, Iceland , June 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025 (the "Convertible Bonds") have elected to convert the principal and accrued interest into ordinary shares of ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that holders of the majority of subordinated convertible bonds, originally issued by Alvotech on November 16, 2022, and December 20, 2022, respectively, with maturity on December 20, 2025 (the “Convertible Bonds”) have elected to convert the principal and accrued interest into ordinary shares of Alvotech at the fixed conversion price of US$10.00 pe ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Alvotech (ALVO) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Alvotech is a member of the Medical sector. This group includes 1042 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank includes 16 different gr ...

Alvotech (ALVO) makes biosimilar versions of branded medicines that have gone off-patent. The year 2024 has been transformational for Alvotech as it marked a gradual transition of ALVO from an R&D company into a full-scale global commercial biologic company.The company recently gained approval for some key biosimilar products like AVT04, its biosimilar to J&J’s (JNJ) blockbuster immunology drug, Stelara, and AVT02, its biosimilar to AbbVie’s (ABBV) blockbuster immunology drug Humira. Alvotech has a commerci ...

Advanz Pharma secures rights to commercialize Alvotech’s biosimilar candidate for Eylea® in Europe Advanz Pharma will leverage its existing specialty and hospital capabilities in Europe to ensure successful market registration, commercialization, and patient access REYKJAVIK, Iceland and LONDON, June 18, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartere ...

Core Insights - Advanz Pharma has entered into an exclusive partnership with Alvotech to commercialize Alvotech's biosimilar candidates for Eylea® in Europe, specifically AVT06 and AVT29 [1][2][3] - Eylea® generated reported sales of $2.9 billion in Europe in 2023, indicating a significant market opportunity for the biosimilar candidates [2] - Advanz Pharma will handle registration and commercialization in Europe, while Alvotech will manage development and supply, with exclusive rights in most European countries [2][3] Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a global leader in the biosimilars market [6] - Advanz Pharma specializes in specialty, hospital, and rare disease medicines, with a commercial presence in over 90 countries and a focus on improving patient access to innovative therapies [8] - The partnership between Alvotech and Advanz Pharma has expanded to include multiple biosimilar candidates, reflecting a strategic collaboration to enhance their market presence [4][3] Product Details - AVT06 and AVT29 are biosimilar candidates to Eylea® that target vascular endothelial growth factors (VEGF) to treat eye disorders [5] - Alvotech announced positive results from a study showing therapeutic equivalence between AVT06 and Eylea®, which is crucial for regulatory approval [3] - The commercialization agreement includes an upfront payment and milestone payments based on development and commercialization achievements [2] Market Context - The biosimilars market is expected to grow, driven by the increasing demand for affordable biologics and the need for broader patient access [3] - Advanz Pharma's strategy includes leveraging its existing capabilities in specialty pharmaceuticals to ensure successful market entry for the biosimilar candidates [1][3] - The partnership aims to capitalize on the significant sales potential of Eylea® and expand the availability of biosimilars in Europe [2][3]